Alentis Therapeutics

Alentis Therapeutics is a Switzerland-based biotechnology company dedicated to developing breakthrough treatments for fibrotic diseases. Founded in 2019, the company is built on groundbreaking research from the laboratory of Professor Thomas Baumert at the University of Strasbourg and Inserm (French National Institute of Health and Medical Research). Its leading drug candidate is a highly selective monoclonal antibody targeting Claudin-1, a novel and previously unexplored target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven cholangiocarcinoma. The company also has early discovery programs exploring the potential of Claudin-1 inhibition in treating fibrosis in other tissues, including the kidneys and lungs, representing vast and expanding markets with unmet needs. Additionally, Alentis utilizes patient-derived drug and target discovery platforms to develop therapies for advanced fibrosis. Unlike current treatments that primarily address fibrosis indirectly, Alentis’ pioneering approach holds the potential to directly modify and reverse disease progression.